RevOpsis Therapeutics has entered a strategic manufacturing collaboration with contract development and manufacturing organisation Kemwell Biopharma to accelerate the development of new multispecific biologics.
SAN CARLOS, Calif. and BANGALORE, India, June 17, 2024 /PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, and Kemwell Biopharma, a leading biologics contract development and manufacturing organization (CDMO), announced today a broad strategic manufacturing partnership. This collaboration aims to accelerate the development of RevOpsis' lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).